Toxicogenomics in non-clinical safety studies: Models of animal and human tissues to assess target organ injury

Genomics: Fundamentals and Applications

Volumn , Issue , 2008, Pages 175-190

  Vickers, Alison ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350477701     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (84)

1. Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicol Pharmacol 2000; 32: 56-67.
2. Greaves P, Williams A, Eve M. First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov 2004; 3: 226-236.
3. Peters TS. Do preclinical testing strategies help predict human hepatotoxic potentials ? Toxicol Pathol 2005; 33: 146-154.
4. Aldridge JE, Gibbon JA, Flaherty MM, et al. Heterogeneity of toxicant response: sources of human variability. Toxicol Sci 2003; 76: 3-20.
5. Fung M, Thornton A, Mybeck K, et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Info J 2001; 35: 293-317.
6. Guengerich FP. Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J Biochem Mol Toxicol 2007; 21: 163-168.
7. Seed J, Carney EW, Corley RA, et al. Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol 2005; 35: 663-672.
8. Huang S-M, Goodsaid F, Rahman A, et al. Application of pharmacogenomics in clinical pharmacology. Toxicol Mechan Meth 2006; 16: 89-99.
9. Thum T, Borlak J. Detection of early signals of hepatotoxicity by gene expression profiling studies with cultures of metabolically competent human hepatocytes. Arch Toxicol 2008; 82: 89-101.
10. Van de Water B, de Graauw M, Le Dévédec S, et al. Cellular stress responses and molecular mechanisms of nephrotoxicity. Toxicol Lett 2006; 162: 83-93.
11. Gunawan BK, Kaplowitz N. Mechanisms of drug-induced liver disease. Clin Liver Dis 2007; 11: 459-475.
12. Farkas D, Tannenbaum SR. In vitro methods to study chemically-induced hepatotoxicity: a literature review. Curr Drug Metab 2005; 6: 111-125.
13. Vickers AE, Fisher R. Precision-cut organ slices to investigate target organ injury. Expert Opin Drug Metab Toxicol 2005; 1: 687-699.
14. Mattes WB. Cross-species comparative toxicogenomics as an aid to safety assessment. Expert Opin Drug Metab Toxicol 2006; 2: 859-874.
15. Malarkey DE, Johnson K, Ryan L, et al. New insights into functional aspects of liver morphology. Toxicol Pathol 2005; 33: 27-34.
16. Laskin DL, Weinberger B, Laskin JD. Functional heterogeneity in liver and lung macrophages. J Leukocyte Biol 2001; 70: 163-170.
17. Roberts RA, Ganey PE, Ju C, et al. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 2007; 96: 2-15.
18. Guillouzo A, Morel F, Ratanasavanh H, et al. Long-term culture of functional hepatocytes. Toxicol In Vitro 1990; 4: 415-427.
19. Schmeichel KL, Bissell MJ. Modeling tissue-specific signaling and organ function in three dimensions. J Cell Sci 2003; 116: 2377-2388.
20. Hamadeh HK, Bushel PR, Jayadev S, et al. Gene expression analysis reveals chemical-specific profiles. Toxicol Sci 2002; 67: 219-231.
21. Huang Q, Jin X, Gaillard ET, et al. Gene expression profiling reveals multiple toxicity end points induced by hepatotoxicants. Mut Res 2004; 549: 147-167.
22. Steiner G, Suter L, Boess F, et al. Discriminating different classes of toxicants by transcript profiling. Environ Health Perspect 2004; 112: 1236-1248.
23. Heijne WH, Slitt AL, van Bladeren PJ, et al. Bromobenzene-induced hepatotoxicity at the transcriptome level. Toxicol Sci 2004; 79: 411-422.
24. Heijne WH, Lamers RJ, van Bladeren PJ, et al. Profiles of metabolites and gene expression in rats with chemically induced hepatic necrosis. Toxicol Pathol 2005; 33: 425-433.
25. Ruepp S, Boess F, Suter L, et al. Assessment of hepatotoxic liabilities by transcript profiling. Toxicol Appl Pharmacol 2005; 207: 161-170.
26. Beyer RP, Fry RC, Lasarev MR, et al. Multicenter study of acetaminophen hepatotoxicity reveals the importance of biological endpoints in genomic analyses. Toxicol Sci 2007; 99: 326-337.
27. Lum PY, He YD, Slatter JG, et al. Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia. Genomics 2007; 90: 464-473.
28. Auman JT, Chou J, Gerrish K, et al. Identification of genes implicated in methapyrilene-induced hepatotoxicity by comparing differential gene expression in target and nontarget tissue. Environ Health Perspect 2007; 115: 572-578.
29. Zideck N, Hellmann J, Kramer P-J, et al. Acute hepatotoxicity: a predictive model based on focused illumina microarrays. Toxicol Sci 2007; 99: 289-302.
30. De Longueville F, Atienzar FA, Marcq L, et al. Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. Toxicol Sci 2003; 75: 378-392.
31. Castro RE, Solá S, Ma X, et al. A distinct microarray gene expression profile in primary rat hepatocytes incubated with ursodeozycholic acid. J Hepatol 2005; 42: 897-906.
32. Burczynski ME, McMillian M, Ciervo J, et al. Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol Sci 2000; 58: 399-415.
33. Harries HM, Fletcher ST, Duggan CM, et al. The use of genomics technology to investigate gene expression changes in cultured human liver cells. Toxicol In Vitro 2001; 15: 399-405.
34. Sawada H, Takami K, Asahi S. A toxicogenomic approach to drug-induced phospholipidosis:analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci 2005; 83: 282-292.
35. Pascussi JM, Gerbil-Chaloin S, Drocourt L, et al. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochem Biophys Acta 2003; 1619: 146-154.
36. Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Therap 2004; 311: 139-146.
37. Baker TK, Carfagna MA, Gao H, et al. Temporal gene expression analysis of monolayer cultured rat hepatocytes. Chem Res Toxicol 2001; 14: 1218-1231.
38. Richert L, Liguori MJ, Abadie C, et al. Gene expression in human hepatocytes is suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab Disp 2006; 34: 870-879.
39. Boess F, Kamber M, Romer S, et al. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci 2003; 73: 386-402.
40. Waring JF, Ciurlionis R, Jolly RA, et al. Isolated human hepatocytes in culture display markedly different gene expression patterns depending on attachment status. Toxicol In Vitro 2003; 17: 693-701.
41. Fielden MR, Kolaja KL. The state of the art in predictive toxicogenomics. Curr Opin Drug Discov Dev 2006; 9: 84-91.
42. Kikkawa R, Fujikawa M, Yamamoto T, et al. In vivo hepatotoxicity study of rats in comparison with in vitro hepatoxicity screening system. J Toxicol Sci 2006; 31: 23-34.
43. Yang Y, Abel SJ, Ciurlionis R, et al. Development of a toxicogenomics in vitro assay for the efficient characterization of compounds. Pharmacogenomics 2006; 7: 177-186.
44. Boess F, Durr E, Schaub N, et al. An in vitro study on 5-HT 6 receptor antagonist induced hepatotoxicity based on biochemical assays and toxicogenomics. Toxicol In Vitro 2007; 7: 1276-1286.
45. Leone AM, Kao LM, McMillian MK, et al. Evaluation of felbamate and other antiepileptic drug toxicity potential base on hepatic protein covalent binding and gene expression. Chem Res Toxicol 2007; 20: 600-608.
46. Hultin-Rosenberg L, Jagannathan S, Nilsson KC, et al. Predictive models of hepatotoxicity using gene expression data from primary rat hepatocytes. Xenobiotica 2006; 36: 1122-1139.
47. Harris AJ, Dial SL, Casciano DA. Comparison of basal gene expression profiles and effects of hepatocarcinogens on gene expression in cultured primary human hepatocytes and HepG2 cells. Mut Res 2004; 549: 79-99.
48. Liguori MJ, Anderson LM, Bukofzer S, et al. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 2005; 41: 177-186.
49. Borlak J, Thum T. Induction of nuclear transcription factors, CYP monooxygenases and GSTA2 gene expression in Aroclor 1254 treated rat hepatocyte cultures. Biochem Pharmacol 2001; 61: 145-153.
50. Olinga P, Merema MT, de Jager MH, et al. Rat liver slices as a tool to study LPS-induced inflammatory response in the liver. J Hepatology 2001; 35: 187-194.
51. Jessen BA, Mullins JS, de Peyster A, et al. Assessment of hepatocytes and liver slices as in vitro test systems to predict in vivo gene expression. Toxicol Sci 2003; 75: 208-222.
52. Vickers AE, Saulnier M, Cruz E, et al. Organ slice viability extended for pathway characterization:an in vitro model to investigate fibrosis. Toxicol Sci 2004a; 82: 534-544.
53. Vickers AE, Rose K, Fisher R, et al. Kidney slices of human and rat to characterize cisplatininduced injury on cellular pathways and morphology. Toxicol Pathol 2004b; 32: 577-590.
54. Vickers AE, Bentley P, Fisher RL. Consequences of mitochondrial injury induced by pharmaceutical fatty acid oxidation inhibitors is characterized in human and rat liver slices. Toxicol In Vitro 2006; 20: 1173-1182.
55. Jung D, Elferink MGL, Stellaard F, et al. Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int 2007; 1: 137-144.
56. Mehendale HM. Tissue repair: an important determinant of final outcome of toxicant-induced injury. Toxicol Pathol 2005; 33: 41-51.
57. Van de Bovenkamp M, Groothuis GMM, Draaisma AL, et al. Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. Toxicol Sci 2005; 85: 632-638.
58. Kasper H-U, Dries V, Drebber U, et al. Precision cut tissue slices of the liver as morphological tool for investigation of apoptosis. In Vivo 2005; 19: 423-432.
59. Hazra S, Miyahara T, Rippe RA, et al. PPAR gamma and hepatic stellate cells. Comp Hepatol 2004; 3: S7.
60. She H, Xiong S, Hazra S, et al. Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem 2005; 280: 4959-4967.
61. Roth RA, Luyendyk JP, Maddox JF, et al. Inflammation and drug idiosyncrasy-Is there a connection? J Pharmacol Exp Therap 2003; 307: 1-8.
62. Ganey PE, Luyendyk JP, Maddox JF, et al. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 2004; 150: 35-51.
63. Liguori MJ, Waring JF. Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions. Expert Opin Drug Metab Toxicol 2006; 2: 835-846.
64. Deng X, Stachlewitz RF, Liguoro MJ, et al. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Therap 2006; 319: 1191-1199.
65. Waring JF, Liguori MJ, Luyendyk JP, et al. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggest a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Therap 2006; 316: 1080-1087.
66. Deng X, Luyendyk JP, Zou W, et al. Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine. J Pharmacol Exp Therap 2007; 322: 852-861.
67. Elferink MG, Olinga P, Draaisma AL, et al. LPS-induced down regulation of MRP2 and BSEP in human liver is due to a posttranscriptional process. Am J Physiol Gastrointest Liver Physiol 2004; 287: G1008-G1016.
68. Zollner G, Fickert P, Zenz R, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001; 33: 633-646.
69. Liu Z-X, Kaplowitz N. Role of innate immunity in acetaminophen-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2006; 2: 493-503.
70. Huang Q, Dunn RT 2nd, Jayadev S, et al. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol Sci 2001; 63: 196-207.
71. Amin RP, Vickers AE, Sistare F, et al. Identification of putative gene-based markers of renal toxicity. Environ Health Perspect 2004; 112: 465-479.
72. Fielden MR, Pearson C, Brennan R, et al. Preclinical drug safety analysis by chemogenomic profiling in the liver. Am J Pharmacogenomics 2005; 5: 161-171.
73. Thukral SK, Nordone PJ, Hu R, et al. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol Pathol 2005; 33: 343-355.
74. Thompson KL, Afshari CA, Amin R, et al. Identification of platform-independent gene expression markers of cisplatin nephrotoxicity. Environ Health Perspect 2004; 112: 488-494.
75. Wei Q, Dong G, Yang T, et al. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 2007; 293: 1282-1291.
76. Yano T, Itoh Y, Matsuo M, et al. Involvement of both tumor necrosis factor-alpha-induced necrosis and p53-mediated caspase-dependent apoptosis in nephrotoxicity of cisplatin. Apoptosis 2007; 12: 1901-1909.
77. Faubel S, Lewis EC, Rezmikov L, et al. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin IL-1β, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Therap 2007; 322: 8-15.
78. Peyrou M, Hanna PE, Cribb AE. Cisplatin, gentamicin and p -aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys. Toxicol Sci 2007; 99: 346-353.
79. Zhou Y, Vaidya VS, Brown RP, et al. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci 2008; 101: 159-170.
80. Trull AK, Facey SP, Rees GW, et al. Serum α-glutathione S -transferases: a sensitive marker of hepatocellular damage associated with acute liver allograft rejection. Transplantation 1994; 58: 1345-1351.
81. Vickers AE, Alegret M, Jimenez RM, et al. Changes in human liver and kidney slice function related to potential side-effects in the presence of biotransformation of four cyclosporine derivatives-CSA, IMM, OG, PSC. In Vitro Mol Toxicol 1998; 11: 119-132.
82. Rokushima M, Omi K, Araki A, et al. A toxicogenomic approach revealed hepatic gene expression changes mechanistically linked to drug-induced hemolytic anemia. Toxicol Sci 2007; 95: 474-484.
83. Sinclair JR, Way W, Vickers AE. Evaluating drug-induced hemolysis effects using whole bloodliver slice co-culture model. The Toxicologist 2007; 249.
84. Vickers AE, Fisher RL, Sinclair JR, et al. Human in vitro hemolysis model to assess drug-induced hemolytic effects. The Toxicologist 2008; 102: 2083.